Press Releases<< Back
CHF Solutions Announces Launch of Aquapheresis Therapy Using Aquadex FlexFlow® System at the Baylor Scott & White Health System in Texas
“Fluid overload continues to be an issue to be managed in the acute and chronic care settings, and CHF Solutions’ Aquadex FlexFlow System has continually proven to be a viable and easy-to-maintain solution for managing these patients and improving their quality of life while reducing the cost of care,” said
About Aquadex FlexFlow® System
The Aquadex FlexFlow system is a clinically proven therapy that provides a safe, effective, and predictable method of removing excess fluid from patients suffering from fluid overload. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and for extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company has submitted an application to the
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the clinical performance of the Aquadex FlexFlow system and the company’s plans to assist clinicians in the care of patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made.
Claudia Napal DraytonChief Financial Officer CHF Solutions, Inc.952-345-4205 email@example.com -or- Bret ShapiroManaging Partner CORE IR 516-222-2560 firstname.lastname@example.org www.coreir.com
Source: CHF Solutions, Inc.